Abstract 364P
Background
Lung cancer treatment gets on the stage of precision medicine. Histopathological classification of lung cancer is crucial in determining optimum treatment. Artificial intelligence (AI) models have been widely shown to be useful in pathological diagnosis and we previously established a reliable AI model to detect the presence of lung cancer on whole slide images (WSIs). However, AI models for the differentiation of major histological types of lung cancer, such as adenocarcinoma (ADC), squamous cell carcinoma (SCC) and small-cell lung cancer (SCLC), are yet to be established.
Methods
We trained a convolution neural network (CNN) based on the EfficientNet-B1 architecture to classify ADC, SCC, SCLC, and non-neoplastic lesion from biopsy specimen WSIs (70, 23, 12 and 171 specimens with ADC, SCC, SCLC and non-neoplastic lesion, respectively) using a training dataset of 276 images of which 60 were reserved for validation. The WSIs were manually annotated by pathologists by drawing around the regions that contain each subtype. We used a transfer learning approach, in which the starting weights were obtained from a pre-trained model on ImageNet. The model was then trained on our dataset using a supervised learning approach. To classify a WSI, the model was applied in a sliding window fashion with an input tile size of 224x224 and a stride of 128 on a magnification of x10. The maximum probability was then used as a WSI diagnosis.
Results
We evaluated our model on a total of 533 WSIs that only had WSI diagnoses. The model achieved a Receiver Operator Curve Area Under the Curves of 0.888 (CI 0.872-0.9075), 0.8913 (CI 0.8596-0.9221), 0.9526 (CI 0.9276-0.9646) for ADC, SCC, and SCLC, respectively.
Conclusions
The obtained results on a large test set are a promising first step towards developing a model for the classification of lung cancer. Our model was only trained on a small dataset of 276 WSIs; however, we hope that the model would be further improved with the collection of additional annotated WSIs for training. Having a high performing model could help reduce the burden on pathologists and be useful for the decision of optimum treatment strategies, such as molecular-targeted therapy, immunotherapy and chemotherapy, according to the histological types of lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Real world outcomes in elderly women with HER2-positive advanced breast cancer
Presenter: Nicole Evans
Session: e-Poster Display Session
52P - Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study)
Presenter: Yookija Kang
Session: e-Poster Display Session
53P - Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2- metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression
Presenter: Indunil Weerasena
Session: e-Poster Display Session
54P - Platinum-based chemotherapy in advanced breast cancer (ABC): Real-world outcome from a tertiary cancer centre in India
Presenter: Indhuja Vijesh
Session: e-Poster Display Session
55P - Eribulin in heavily pretreated metastatic breast cancer: A real-world data from India
Presenter: Tanmoy Mandal
Session: e-Poster Display Session
56P - Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
Presenter: Yiqi Yang
Session: e-Poster Display Session
57P - Therapeutic vulnerability of malignant phyllodes tumour to pazopanib identified through a novel patient-derived xenograft and cell line model
Presenter: Dave Ng
Session: e-Poster Display Session
58P - Survival benefit of local treatments in breast cancer with lung metastasis: Results from a large retrospective study
Presenter: Yimeng Chen
Session: e-Poster Display Session
59P - The impact of site of metastasis on overall survival in indigenous and non-indigenous patients of Western Australia with breast cancer
Presenter: Azim Khan
Session: e-Poster Display Session
60P - Risk factors of bone metastasis and skeletal-related events in high-risk breast cancer patients
Presenter: Sumadi Lukman Anwar
Session: e-Poster Display Session